Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 269 No 7221 p596
26 October 2002

This article
Reprint
Photocopy


News summary

 


Maximum prices for generics to remain

Discussions about what mechanism should replace the maximum prices scheme for generic medicines are set to continue and, for the time being, the existing arrangements will remain in place.

The Department of Health announced last week that good progress is being made with developing long-term arrangements to replace the existing scheme. However, it was not able to put these in place before an annual review of the maximum prices scheme, required under European law, had to be carried out. It therefore proposes to extend the current scheme unchanged. “Economic factors do not, in our view, support the case for an adjustment in the level of maximum prices in either direction,” the Department says in a consultation letter sent to interested parties. Comments on the proposals are invited by 29 November with the scheme being officially extended from 16 December.

According to the Department, since the maximum prices scheme was introduced in August 2000 the supply of generics to community pharmacies has remained stable and the National Health Service has been protected from the price rises seen in 1999.

The two long-term options which the Department is studying are for a system of reference, or fixed, prices (based on data supplied by manufacturers and wholesalers) or for central competitive tendering (PJ, 28 July 2001, p109). Bodies representing pharmacy contractors have proposed a benefit-sharing model for generics under which pharmacists would be able to retain some of the savings achieved through competitive purchasing arrangements (PJ, 27 October 2001, p585).

The British Generic Manufacturers Association said that it was disappointed that it had been necessary, yet again, to roll over the maximum prices scheme, which many companies were reporting problems with. The BGMA under stands that the Government is continuing to have separate meetings with manufacturers and wholesalers about its proposals for long-term arrangements for generics.
A link to the Department’s consultation letter can be found on the PJOnline links page (www.pjonline.com/links).

 

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal